financetom
Technology
financetom
/
Technology
/
Musk's Starlink receives India's final regulatory nod for launch, sources say
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Musk's Starlink receives India's final regulatory nod for launch, sources say
Jul 9, 2025 3:11 AM

BENGALURU (Reuters) -Starlink has received a license from India's space regulator to launch commercial operations in the country, clearing the only remaining regulatory hurdle for the satellite provider to enter the market, three sources familiar with the matter told Reuters.

The Elon Musk-led firm has been waiting since 2022 for licences to operate commercially in India. Last month it received a key license from India's telecom ministry to launch, but has been waiting for a go ahead from India's space department.

Starlink and the space department did not immediately respond to requests for comment.

Starlink would be the third company to receive India's nod to enter the space, with India previously approving applications by Eutelsat's OneWeb and Reliance Jio to provide services in the country.

Starlink will now need to secure spectrum from the government, set up ground infrastructure, and also demonstrate through testing and trials that it meets the security rules it has signed up for.

Musk and billionaire Mukesh Ambani's Jio clashed for months over how India should grant spectrum for satellite services. India's government sided with Musk that spectrum should be assigned and not auctioned.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AppLovin Announces Succession Plans for Key Leadership Roles and New Independent Chairperson
AppLovin Announces Succession Plans for Key Leadership Roles and New Independent Chairperson
Apr 7, 2026
PALO ALTO, Calif.--(BUSINESS WIRE)-- AppLovin Corporation ( APP ) (“AppLovin” or the “Company”), the leading marketing platform, today announced succession plans relating to its executive management team and the appointment of Craig Billings as independent Chairperson of its Board of Directors (the “Board”). The Company announced the following management succession plans: Chief Technology Officer: Basil Shikin, AppLovin’s current Chief Technology...
At ASCRS/ASOA 2026, the Saffron Solution Exposes the Hidden Operational Leaks Costing Ophthalmology Practices Growth, Access, and Revenue
At ASCRS/ASOA 2026, the Saffron Solution Exposes the Hidden Operational Leaks Costing Ophthalmology Practices Growth, Access, and Revenue
Apr 7, 2026
As ASCRS and ASOA 2026 begin, a new model for ophthalmology practices emerges—focused on eliminating operational gaps, improving patient access, and driving measurable growth WASHINGTON, April 7, 2026 /PRNewswire/ -- As ASCRS and ASOA 2026 convene this week in Washington, D.C., the Saffron Solution is shifting the conversation in ophthalmology from incremental tools to a more urgent reality: most practices are not...
TransAlta to Host Annual and Special Meeting of Shareholders and First Quarter 2026 Results Conference Call
TransAlta to Host Annual and Special Meeting of Shareholders and First Quarter 2026 Results Conference Call
Apr 7, 2026
CALGARY, Alberta, April 07, 2026 (GLOBE NEWSWIRE) -- TransAlta Corporation ( TAC ) 2026 Annual and Special Meeting of TransAlta Corporation Shareholders On Thursday, April 30, 2026, TransAlta Corporation ( TAC ) will hold its annual and special meeting of shareholders at 11:30 a.m. Mountain Time (1:30 p.m. Eastern Time) in a virtual-only meeting format via live audio webcast (https://meetings.lumiconnect.com/400-012-606-918)....
NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update
NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update
Apr 7, 2026
Successful transformation to global biotech platform with two mid-stage potential best-in-class/first-in-class programs, givastomig and VIS-101, with compelling proof-of-concept dataGivastomig, a potential best-in-class/first-in-class Claudin 18.2-directed bispecific antibody for gastric cancer, has shown robust and durable responses with broad CLDN18.2 activity, favorable safety, as well as potential eligibility for FDA’s Accelerated Approval Pathway with potential initiation of a registrational Phase 3 trial...
Copyright 2023-2026 - www.financetom.com All Rights Reserved